Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.7%

119 terminated/withdrawn out of 2104 trials

Success Rate

91.1%

+4.6% vs industry average

Late-Stage Pipeline

4%

93 trials in Phase 3/4

Results Transparency

36%

439 of 1217 completed trials have results

Key Signals

341 recruiting439 with results78 terminated41 withdrawn

Enrollment Performance

Analytics

Phase 2
676(41.7%)
Phase 1
476(29.3%)
N/A
338(20.8%)
Phase 3
82(5.1%)
Early Phase 1
40(2.5%)
Phase 4
11(0.7%)
1623Total
Phase 2(676)
Phase 1(476)
N/A(338)
Phase 3(82)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2104)

Showing 20 of 2104 trials
NCT00579566Recruiting

Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

Role: lead

NCT04761055Not ApplicableCompleted

Study of iBreast, a Handheld Device to Detect Breast Abnormalities During Screening Visits for Breast Cancer

Role: lead

NCT06616636Phase 1Recruiting

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

Role: collaborator

NCT01025089Phase 2Active Not Recruiting

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

Role: lead

NCT01542021Not ApplicableCompleted

Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

Role: lead

NCT01587352Phase 2Active Not Recruiting

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Role: collaborator

NCT06039930Not ApplicableRecruiting

Tele-PROTECT Therapy: Effectiveness, Empowerment, and Implementation

Role: collaborator

NCT00505063Phase 2Completed

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

Role: lead

NCT07303894Phase 2Recruiting

A Study of Isoquercetin in People With Ovarian Cancer

Role: lead

NCT06057948Phase 2Recruiting

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Role: lead

NCT07089992Phase 2Recruiting

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

Role: lead

NCT06773195Phase 1Recruiting

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

Role: lead

NCT04743661Phase 2Active Not Recruiting

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Role: collaborator

NCT06563479Phase 3Recruiting

A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer

Role: lead

NCT07099391Phase 1Recruiting

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

Role: lead

NCT06801067Phase 1Recruiting

A Study of SER-155 to Treat Diarrhea in People on Immunotherapy

Role: lead

NCT04577326Phase 1Active Not Recruiting

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Role: lead

NCT01339052Phase 2Completed

Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

Role: collaborator

NCT04208490Not ApplicableCompleted

Implementation and Effectiveness Trial of HN-STAR

Role: collaborator

NCT02244411Not ApplicableCompleted

Exercise and QUality Diet After Leukemia: The EQUAL Study

Role: lead